Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy

Kathleen C Suozzi; Maximilian Stahl; Christine J Ko; Anne Chiang; Scott N Gettinger; Mark D Siegel; Christopher G Bunick

doi:10.1016/j.jdcr.2016.05.002

Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy

JAAD Case Rep. 2016 Jul 14;2(3):264-8. doi: 10.1016/j.jdcr.2016.05.002. eCollection 2016 May.

Authors

Kathleen C Suozzi¹, Maximilian Stahl², Christine J Ko¹, Anne Chiang³, Scott N Gettinger³, Mark D Siegel², Christopher G Bunick¹

Affiliations

¹ Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
² Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.
³ Department of Medicine, Yale University School of Medicine, New Haven, Connecticut; Smilow Cancer Center, Yale University School of Medicine, New Haven, Connecticut.

No abstract available

Keywords: CTLA-4, cytotoxic T-lymphocyte–associated antigen 4; PD-1, programmed death–1; immune-related adverse events; immunotherapy; irAEs, immune-related adverse events; lung cancer; sarcoidosis.

Publication types

Case Reports